Log In
Print
BCIQ
Print
Print this Print this
 

orBec, beclomethasone dipropionate

  Manage Alerts
Collapse Summary General Information
Company Soligenix Inc.
DescriptionOral locally-acting therapy consisting of 2 tablets, 1 intended to release beclomethasone dipropionate (BDP) in the proximal portions of the GI tract and the other to release BDP in the distal portions
Molecular Target Glucocorticoid receptor (GCCR)
Mechanism of Action 
Latest Stage of DevelopmentPhase II
IndicationGraft-versus-host disease (GvHD)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today